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The complex pathogenesis of immune-mediated inflammatory diseases (IMIDs) has been extensively
investigated and dysregulation of cytokines, such as tumour necrosis factor (TNF), has been shown to
play a dominant role in the pathogenesis of various 1MIDs, such as rheumatoid arthritis, ankylosing
spondylitis, Crohn's disease, ulcerative colitis, psoriasis and psoriatic arthritis. The subsequent
development of biological agents capable of blocking TNF has led to important advances in the
pharmacotherapy of such diseases and confirmed the concept of a common pathophysiology among
IMIDs with TNF having a predominant role. Five TNF inhibitors have currently been approved for
treatment of one or more IMIDs; these include infliximab, etanercept, adalimumab, golimumab and
certolizumab pegol. Given the similarities in the pathogenic background of IMIDs, one could expect
that anti- TNF agents be similarly effective and with comparable tolerability profiles; however, this may
not be the case. Structural and pharmacological differences among the anti-TNF drugs are likely to
result in differences in efficacy and tolerability among the agents in the different IMIDs, together with
differences in potency, therapeutic dose ranges, dosing regimens, administration routes, and propensity
for immunogenicity. Among the five TNF inhibitors approved for treatment of IMIDs, adalimumab has
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the widest range of indications. Data from controlled clinical trials of adallmumab, showing its excellent
efficacy and tolerability in a wide range of indications, are supported by real-world long-term data from
observational studies, which confirm the value of adalimumab as a suitable choice in the management
of 1MIDs.
In recent years, the complex pathogenesis
of immune-mediated inflammatory diseases
(IMlDs) have been elucidated and dysregulation
of cytokines has been shown to play a major role.
Consequently, treatments for IMIDs have moved
away from an approach mainly based on symptom
relief (i.e. analgesics, steroids, and non-steroidal
anti-inflammatory drugs [NSAlDs] such as
cyclooxygenase-2 inhibitors) to a mechanism-based
strategy, in which biological therapies target specific
dysregulated proteins or cell receptors that have
been shown to playa key role in the altered immune
response underlying these disorders (1). As a result,
the traditional symptom-based approach meant
that individual chronic inflammatory diseases were
treated by the specialist for that particular organ,
whereas a mechanism-based strategy demands a
more holistic multi-disciplinary approach.
Over expression of tumour necrosis factor (TNF)
has been shown to play a dominant role in the
pathogenesis of various IMIDs, such as rheumatoid
arthritis (RA), ankylosing spondylitis (AS), Crohn's
disease, ulcerative colitis (UC), psoriasis and
psoriatic arthritis (PsA). In addition to evidence
from mechanistic studies, pointing out the common
pathogenesis and role ofTNF among IMlDs, findings
from epidemiological and genetic studies support
the theory that IMlDs are related disorders, with
a common genetic susceptibility, thus explaining
the co-occurrence or 'genetic overlap' and familial
patterns of these diseases (2-6).
The subsequent development ofbiological agents
able to block TNF has led to important advances
in the pharmacotherapy of such diseases (7). The
effectiveness of targeted anti-TNF therapy in many
different IMlDs has confirmed, indeed, the concept
of a common pathogenesis, with TNFa having a
central role (7). TNF inhibitors have been shown to
promote dramatic clinical remission and improved
quality oflife (QoL) even in patients with inadequate
response to conventional pharmacotherapy. They are
also well tolerated, can prevent disease progression,
and in many cases they have been shown to reverse
the target organ damage in different disorders (7-13).
Five TNF inhibitors have currently been
approved for the treatment of one or more IMlDs;
these include infliximab, etanercept, adalimumab,
golimumab and certolizumab pegol. Each agent has
been approved for specific therapeutic indications,
some of which coincide. Among the available anti-
TNF agents, adalimumab has received regulatory
approval in nine IMID indications to date. As such, it
has the widest approved use of all biological agents
and could, therefore, be best suited for treatment of
these combined and co-occurring disorders.
Objective and methodology
The aim of this narrative review is to review
pharmacological and clinical data on the differences
among the available anti-TNF agents, as well as to
review clinical trials and real-world data on the use
ofadalimumab in the treatment ofIMlDs. Combined
automated and manual literature searches were
performed on PubMed using the search terms 'anti-
TNF'/'anti-TNF-alpha [a]'/'TNF inhibitor'/'TNF-
alpha [a] inhibitor' AND ('rheumatoid arthritis'
OR psoriatic arthritis' OR 'psoriasis' OR 'axial
spondyloarthropathy' OR 'ankylosing spondylitis'
OR 'Crohn's disease' OR 'ulcerative colitis' OR
'juvenile idiopathic arthritis'). Appropriate papers
for this review were manually selected from the
search results and the bibliographies of previous
review articles.
Differences among anti- TNF agents
Structural differences
Anti-TNF drugs are either whole antibodies
(infliximab, adalimumab and golimumab) or contain
fragments of antibody in their structure (etanercept
and certolizumab). Antibody structure (an Fe domain
connected to two antigen binding Fab' domains)
means that it can bind two molecules of the same
antigen simultaneously. The Fe domain interacts
with specific receptors, designated as Fe-Rn and
Fcy-R (14). Fe-Rn is expressed mainly on endothelial
cells of blood vessels, enabling antibodies to adhere
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to the inner surface of vessels and then return to the
circulation in an active form. In this way, vascular
endothelium acts as a depot to prolong the half-life of
circulating antibodies. Fcy-R receptor is expressed on
various cell populations and mediates phagocytosis,
production of cytokines or antibodies, complement-
dependent cytotoxicity (CDC), antibody-dependent
cell cytotoxicity (ADCC) and degranulation of mast
cells or granulocytes (15, 16).
Being whole IgG1 monoclonal antibodies,
infliximab, adalimumab and golimumab, bivalently
bind TNF, to form multimeric 'antigen-antibody'
complexes. Adalimumab and golimumab are fully
human monoclonal antibodies (17, 18), whereas
infliximab is a mouse-human chimeric monoclonal
antibody (19). Etanercept is the only soluble TNF
inhibitor consisting of a constant Fe fragment of
human IgG I connected via a hinge region to two
extracellular human TNF receptor (TNFR) domains
(20). Unlike infliximab, adalimumab and golimumab,
etanercept forms a monovalent bond with TNF,
likely because of a lack of flexibility of the hinge
region. Certolizumab pegol consists of single IgG I
Fab' fragment of a humanized monoclonal antibody
bound to two 20-kD polyethylene glycol chains;
the resulting expanded molecular mass increases
the plasma half-life of the drug (21). Since it is not
equipped with an Fe region, certolizumab interacts
with TNF in a monovalent fashion (15, 22).
TNF exists either as a soluble TNF (sTNF) or a
transmembrane TNF (tmTNF) exposed on the surface
ofTNF-expressing cells. All anti-TNF agents bind to
and neutralize sTNF and exert different effects on
tmTNF-expressing cells, but differences in affinity
and avidity for sTNF and tmTNF have been observed
(23). Differences in the molecular structures of anti-
TNF drugs result in differences in pharmacokinetic
and pharmacodynamic profiles, as described below,
and give rise to variations in the anti-TNF effect on
cell apoptosis, CDC and ADCC (23).
Pharmacodynamic differences
The most significant pharmacodynamic
differences among anti-TNF drugs may be grouped
into two main categories: 1) the ability to form
complexes and 2) the presence or absence of an Fe
region,
Ability to form complexes
A differential ability to establish links with the
divalent or monovalently bound TNF determines
whether large or small drug-TNF complexes are
formed and influences their ability to activate
reverse signalling processes (23). Large molecular
complexes, generated by binding of TNF with
infliximab, adalimumab or golimumab, allow: a)
high stability of the drug-sTNF complex; b) faster
clearance of these complexes from the bloodstream;
c) slower dissociation of sTNF from the drug (this
property translates into a reduced ability of sTNF to
be released from the antibody binding, to return free
in the bloodstream and to regain its pro-inflammatory
activity); d) a greater ability to activate processes
of reverse signalling by tmTNF, resulting in an
enhancement of the anti-inflammatory activity. By
contrast, small complexes, formed when sTNF binds
with etanercept or certolizumab, are characterized
by: a) reduced stability; b) slow rate of removal
from the bloodstream; c) high speed of dissociation
of sTNF from the drug with reacquisition of pro-
inflammatory activity; d) complexes oftmTNF with
etanercept or certolizumab show less or no ability to
evoke anti-inflammatory processes through reverse
signalling (22, 24).
Presence or absence ofFe region
The presence or absence of the antibody Fe
region in the drug molecule determines whether the
drug can activate Fc-dependent effects, including
CDC andADCC (22, 24).
Different propensities to activate CDC and
ADCC may explain the differences in clinical effects
observed with different anti-TNF agents, with those
also having CDC and ADCC activity being more
effective clinically than those that only neutralise
TNF.
Since infliximab, adalimumab and golimumab
are equipped with a complete Fe region, they can
interact with Fcy-R and activate Fc-dependent effects,
including CDC and ADCC. These drugs also interact
with Fe-Rn, allowing them to remain in circulation,
or extend their plasma half-life. Etanercept, despite
being equipped with an Fe region, does not have the
CH 1 domain, and this feature seems to explain its
low propensity to induce CDC. Moreover, the Fe
region of etanercept shows a low affinity for Fe-Rn,
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and this could explain its shorter plasma half-life.
Certolizumab is devoid ofan Fe region and therefore
cannot induce CDC or ADCC (25, 26).
Pharmacokinetic differences
The pharmacokinetic profiles of anti-TNF in
humans are difficult to compare due mainly to the
lack of direct comparative studies and also because
of the different dosages, routes and frequencies of
administration. Nevertheless, some authors have
used algorithms to extrapolate the pharmacokinetic
profiles of these drugs at the steady state in order
to allow comparisons among them. Infliximab,
being administered intravenously, reaches high
peak plasma concentrations (C
max
; 118-192 mg/L)
in approximately 7 days (Trna)' followed by marked
reductions in circulating levels to <1 mg/L just prior
to administration of the next dose (trough serum
concentration). By contrast, adalimumab, golimumab,
etanercept and certolizumab, being administered by
subcutaneous injection, reach lower C (4.7-7.7,
max
5-6, 1.1-2.4, and 43--49 mg/L, respectively) in
shorter T (approximately 5.5, 2-6, 2.1-3 and 2.2-
max
7.1 days, respectively). Although Cmax are lower than
those achievable with infliximab, they are subject to
less fluctuation between one administration and the
next. Another important parameter, which affects the
duration of the anti-TNF effect, is the long plasma
half-life (t I /2) , which is an index of the propensity
of a drug to remain in the bloodstream. Although
published data are heterogeneous (infliximab, 7.7-
12 days; adalimumab, 10-20 days; golimumab,
7-20 days; etanercept, 3-4 days; and certolizumab,
14 days), etanercept's shorter half-life than the other
anti-TNF agents may be due to its low binding
affinity for vascular endothelial Fe-Rn receptors (24,
26). The lack of a Fe region prevents certolizumab
from interacting with the vascular endothelial Fe-Rn
receptors (15). This should favour blood clearance
of certolizumab with a faster subsequent reduction
of its plasma half-life. However, this problem has
been solved via the addition of two PEG chains,
which allow the compound to remain in the blood
circulation with a plasma half-life comparable to that
of infliximab, adalimumab and golimumab.
Differences in efficacy
Since TNF has a central role in the pathogenesis
and pathophysiology of IMIDs, one would expect
that all five anti-TNF agents - adalimumab,
etanercept, infliximab, certolizumab pegol and
golimumab - would be similarly effective in the
treatment of patients with any IMID; however, this
does not appear be the case. Among the five agents,
although infliximab and etanercept were introduced
first, adalimumab has been shown to be effective
for the widest range of indications. Within specific
indications, direct head-to-head comparisons of
efficacy are lacking (27) and data on the differences
in clinical efficacy among the anti-TNF drugs by
indirect comparisons are not reliable.
Not surprisingly, most data have been published
for RA. A large Bayesian meta-analysis of studies
of biological agents in RA (28) showed differences
in efficacy of anti-TNF drugs used in combination
with the disease-modifying anti-rheumatic drug
(DMARD) methotrexate (MTX). In this analysis,
etanercept was significantly more effective in
improving American College of Rheumatology
(ACR) 20/50/70 outcomes as compared with
adalimumab and infliximab, without significant
differences between etanercept and certolizumab
pegol (28). However, an indirect comparison of the
efficacy of eight biologics (including certolizumab
pegol, infliximab, etanercept, adalimumab and
golimumab) in RA, based on ACR50 outcome,
showed that the efficacy among the agents was not
significantly different, although all were significantly
more effective than MTX and placebo (29). Another
systematic review showed that the efficacy of all
five anti-TNF agents was significantly higher than
placebo but similar to MTX, and that the anti-TNF/
MTX combination was superior to either MTX or
TNF-blocker alone, without differences among the
anti-TNF agents (30). No difference in efficacy
was also shown in another systematic indirect
comparison (31).
The mechanism for increased efficacy of anti-
TNF agents with MTX versus anti-TNF alone is not
clear, but greater longer-term effectiveness with the
combination may be due to a reduced likelihood of
anti-drug antibody (ADA) formation with adjunctive
MTX; this is certainly observed with infliximab
therapy. This issue is discussed in more detail in the
section entitled'Advantages of combination therapy
with MTX' below.
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A dose-response meta-analysis, performed for
quantifying the relative efficacy of biologics in RA,
showed that, although all anti-TNF displayed a similar
dose-response relationship, significant differences in
efficacy among the anti-TNF were observed due to
differences in the clinical dose ranges available: at
the suggested starting dose, golimumab was the least
efficacious, followed by infliximab, adalimumab,
etanercept, and certolizumab (32).
Some data suggest that the TNF inhibitory effect
varies among the agents, translating into different
consequences for the highly complex pathogenic
mechanisms involved in the various forms of IMID.
Differences in the efficacy and tolerability among
the anti-TNF agents in different IMIDs are likely to
depend on structural and pharmacological differences
among the agents.
Administration and regimen differences
Anti-TNF agents are given either as subcutaneous
injection (etanercept, adalimumab, certolizumab and
golimumab) or intravenously (infliximab). Although
the intravenous infusion of infliximab has to be
performed at the clinical or infusion centre, it only has
to be administered once every 4-8 weeks. Etanercept,
adalimumab, certolizumab and golimumab can be
self-administered, but they are given more frequently
(once or twice a week for etanercept, every 2 weeks
for adalimumab and certolizumab, and every 4 weeks
for golimumab).
Patients with AS were shown to appreciate having
a choice in their anti-TNF therapy and cited different
reasons for choosing intravenous or subcutaneous
therapies (33). For infliximab, patients reported a
reduced frequency of injections, administration by
a trained professional and use of infusion time for
leisure activities as the reasons for their preference,
whereas for subcutaneous anti-TNF drugs, patients
cited flexibility with timing of treatment, shortened
administration time and convenience as the main
reasons for their choice (33). In RA patients, results
from the RIVIERA survey - a questionnaire-based
study investigating patient preferences of anti-
TNF therapies in RA - showed that the treatment
choice was important to patients and approximately
half preferred intravenous and half subcutaneous
administration (34). Reasons for choosing
intravenous therapy were safety and reassuring
physician presence, whereas reasons for choosing
subcutaneous therapy were convenience and home
treatment (34). Generally younger patients prefer
self-administration and older patients prefer to visit
a clinic (35). In patients with inflammatory bowel
disease (18D), two-thirds indicated a preference
for intravenous or subcutaneous anti-TNF, whereas
one-third of patients did not indicate a preference
for either, and a trend towards a preference for
infliximab versus adalimumab was reported; most
of the patients who preferred infliximab did not like
the idea of self-injecting, and most patients who
preferred adalimumab appreciated the convenience
of injecting at home; other reasons cited for the
choice were the frequency of administration, mode
of administration, or differing 'times in the market-
place'; infliximab has been on the market for a longer
period of time in Crohn's disease than adalimumab
(36).
Differences in immunogenicity
Although current evidence for differences in
efficacy among anti-TNF agents is inconsistent, such
differences tend to emerge when the therapeutic
response to one anti-TNF agent is lost over time, but
patients retain the ability to respond to other drugs
of the same class (15, 26). A systematic review of
28 studies showed an improvement in effectiveness
with a second anti-TNF agent (adalimumab,
etanercept or infliximab) as compared with the
therapeutic response achieved before switching,
in patients who had discontinued a previous TNF
inhibitor (27). The increasing lack of therapeutic
response over time is thought to depend mainly on
the formation of ADAs - a process that has been
reported with many biological drugs and has been
associated with all five anti-TNF agents, although
with varying degrees of incidence, depending on
the molecule and disease being considered (37).
The immunogenicity displayed by adalimumab and
infliximab appears to be linked to subtherapeutic
serum drug levels and a loss of clinical response,
while for etanercept, golimumab and certolizumab,
data on immunogenicity are quite limited (38).
However, based on current evidence, immune cross-
reactivity among anti-TNF drugs does not appear to
occur. Additional research, aimed at assessing the
immunogenicity ofanti-TNF drugs (39), determining
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optimal treatment regimens and the concomitant use
of DMARDs e.g. MTX and immunosuppressants, to
minimize ADA formation or investigating the use of
neutralizing immunotherapy to reduce the likelihood
ofADA formation, is presently ongoing (37).
Differences in safety profile
Among the five TNF inhibitors approved for
treatment of one or more IMlDs - infliximab,
etanercept, adalimumab, golimumab and
certolizumab pegol- most tolerability issues appear
to be class effects (e.g. increased risk of some
malignancies, serious infections and tuberculosis
reactivation (40», and there are very few clinically
relevant differences among these agents apart
from those related to the administration (e.g.
infusion reaction with infliximab); however, data
on certolizumab pegol and golimumab are limited
(41). Findings from a recent meta-analysis suggest
that etanercept may have the best tolerability profile
in RA (30); tuberculosis and other granulomatous
infections may occur more frequently with
monoclonal anti-TNF antibodies, such as infliximab
and adalimumab, than with soluble TNF receptors
such as etanercept (42). Demyelination has been
reported with etanercept, infliximab and adalimumab
and is likely to occur also with the newer agents.
Therefore, anti-TNF agents are contraindicated in
patients with multiple sclerosis (41). Screening is
advised to identify patients with multiple sclerosis,
other demyelinating diseases, latent tuberculosis,
HIV and hepatitis infection, to allow a risklbenefit
analysis to be performed in the individual patient
(41). Long-term safety data are limited even for
etanercept, infliximab and adalimumab in RA (43)
and interpreting long-term safety data is complicated
by the fact that the same adverse events (AEs) are
noted to be elevated in patients with autoimmune
disease even in those not receiving biological therapy
(44). All agents appear to have a propensity to trigger
the development of anti-nuclear antibodies (ANAs)
and double-stranded DNA antibodies (dsDNA-Abs)
as well as to cause auto-immune diseases such as
lupus-like disease or vasculitis, but the risk may be
higher with infliximab (41).
All the anti-TNF agents are thought to be safe, at
least for short-term therapy, in early stage pregnancy
(45); however, they cross the placenta from the end
of the second trimester, and, due to some reports of
increased infection rates in children exposed in utero
and concerns about the impact on the developing
immune system, experts have suggested that anti-
TNF drug therapy should be stopped during the
second trimester (45).
Advantages ofcombination therapy with MTX
All anti-TNF agents can be given as monotherapy
in patients unresponsive to or unable to tolerate
MTX (apart from infliximab and golimumab in RA
which must be given with MTX). In RA, biological
therapy plus MTX has been shown to be more
effective than MTX alone, even in patients with
an inadequate response to MTX prior to initiation
of the biological therapy (46, 47). The advantages
of combination therapy with MTX have also been
observed in patients with early RA with minimal or
no previous MTX treatment (48).
Although the mechanism is not known,
concomitant use of MTX appears to reduce the
immunogenicity of the anti-TNF agent and thus
the risk of ADA formation (49, 50). Due to the
particularly high risk of immunogenicity reported
with infliximab in RA, concomitant use of MTX is
required, and this combination appears to reduce the
need for dose escalation over time (51).
Evidence comparing efficacy among the anti-
TNF drugs with MTX is limited, but a Bayesian
mixed-treatment comparison of the efficacy of
anti-TNF agents in RA patients, who did not
previously respond to MTX alone, highlighted some
differences. In particular, using ACR 20/50 and
Health Assessment Questionnaire [HAQ] scores,
etanercept was more effective than infliximab and
golimumab, and certolizumab was more effective
than infliximab and adalimumab (52). Analysis of
ACR outcomes showed an improved efficacy of
certolizumab versus golimumab, and HAQ analysis
showed that adalimumab, certolizumab, etanercept
and golimumab were superior to infliximab, and
etanercept displayed higher efficacy as compared
with adalimumab (52).
Evidencefor efficacy ofadalimumab in IMIDs
The pivotal randomized controlled trials (RCTs)
of adalimumab in all approved indications are
summarised in Table 1.
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Controlled clinical trials
Rheumatoid arthritis
In a I-year multicentre study, adalimumab
plus MTX was more effective than MTX alone at
inhibiting the progression of structural joint damage,
reducing the signs and symptoms, and improving
physical function in 619 patients with active RA who
had an inadequate response to MTX (53). Similarly, in
the I-year PREMIER study the combination therapy
with adalimumab plus MTX was more effective in all
outcomes measured than MTX alone or adalimumab
alone in patients with early, aggressive RA who had
not previously received MTX treatment (54).
Juvenile idiopathic arthritis (juvenile rheumatoid ar-
thritis)
In the 48-week DE038 study adalimumab plus
MTX was more effective than MTX or adalimumab
alone or placebo, and this combination was well
tolerated in children aged 4 to 17 years with active
juvenile RA who had previously received treatment
with NSAIDs (55).
Ankylosing spondylitis
The Adalimumab Trial Evaluating Long-Term
Efficacy and Safety in AS (ATLAS) study was a
randomised, double-blind, placebo controlled, 24-
week trial in which adalimumab was shown to have
significantly greater efficacy over 24 weeks versus
placebo (56). Although the rates of AEs was higher
with adalimumab as compared with placebo, the
rates of infections was similar and most AEs were
mild-to-moderate(56). The subsequent 2-year open-
label extension study showed that the efficacy was
improved or maintained up to 2 years and that the
long-term adalimumab treatment was well tolerated,
without cases of tuberculosis, congestive heart
failure, lupus-like symptoms, or demyelinating
disease (57).
Psoriatic arthritis
In the ADEPT randomized, double blind,
placebo-controlled study in 313 patients with active
PsA, adalimumab significantly improved all efficacy
variables including joint and skin symptoms, and
disability; it counteracted also the structural changes
as compared with placebo, and was well tolerated.
In the long-term open-label extension ofADEPT, the
clinical and radiographic efficacy ofadalimumab was
sustained and the risk-benefit profile in patients with
PsA was favourable over the 2 years of treatment
(58, 59).
Psoriasis
In the REVEAL study - a 52-week, multicentre
trial - 1212 patients with chronic plaque psoriasis
were randomized to receive adalimumab (40 mg) or
placebo every other week (eow) for the first 15weeks,
and then, depending on ~75% improvement in PASI
score, subjects were re-randomised to adalimumab
or placebo (60, 61). A ~75% improvement in PASI
score was achieved in 71% of patients receiving
adalimumab and only 7% in placebo recipients. A
loss of response was then observed in 28% of the
patients re-randomised to placebo and only 5%
treated with adalimumab (60).
In the 16-week CHAMPION study, 271 patients
with moderate-to-severe chronic plaque psoriasis
were treated with adalimumab, MTX or placebo;
adalimumab was shown to provide superior efficacy
and more rapid improvements as compared with
either MTX or placebo, with similar patterns of
tolerability (62).
Crohn sdisease
In the CHARM study, conducted on 854 patients
with moderate-to-severe Crohn's disease, the
enrolled subjects received open-label adalimumab
for 4 weeks and were then stratified by response,
defined as a decrease in Crohn's Disease Activity
Index (CDAI) of ~70 points from baseline, and
randomized to adalimumab 40 mg eow or weekly
or placebo for additional 52 weeks. Rates of
clinical remission (CDAI <150) were significantly
higher with adalimumab versus placebo at 26 and
56 weeks of treatment, but no differences between
the eow and weekly dose regimens were recorded
(63). In a subgroup analysis of the CHARM trial,
stratification by disease duration showed that
adalimumab treatment resulted in greater remission
rates than placebo over 1 year regardless ofduration;
in Crohn's disease patients treated for 3 years, the
remission rates with adalimumab were the highest
in patients with the shortest disease duration, and
the incidence of serious AEs was also lower in this
group (64).
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In the CLASSIC II trial, the efficacy of open-
label adalimumab for maintaining remission in
Crohn's disease was evaluated in 55 patients who
achieved remission with adalimumab in CLASSIC I
(n=299) (65). In these patients, the remission at week
56 was achieved by 79% with eow treatment, 83%
with weekly adalimumab and 44% with placebo.
In addition, 204 patients, who did not achieve
remission, received open-label adalimumab 40 mg
eow and 46% achieved remission at week 56 (65).
In the EXTEND trial, of 135 patients with
moderate to severe ileocolonic Crohn's disease,
those receiving adalimumab were significantly more
likely to achieve and maintain muscosal healing
and achieve clinical remission than those receiving
placebo (66).
Ulcerative colitis
In the l-year randomized, double-blind,
placebo-controlled ULTRA 2 study, adalimumab
was more effective than placebo in achieving and
maintaining clinical remission. It was also well
tolerated in patients with moderate-to-severe UC
with an inadequate response to conventional steroid
or immunosuppressant therapy (67). In a subgroup
analysis of 248 patients treated with adalimumab,
123 (49.6%) achieved a response at week 8, and of
these 30.9%, achieved clinical remission at week
52; early response was a significant predictor of a
positive outcome at I year (68).
Observational clinical practice studies
Findings from post-registration observational
studies have substantially confirmed that the
outcomes recorded in RCTs can legitimately be
extrapolated to the patients managed in the clinical
practice.
Inflammatory bowel diseases
An observational study in UC showed that
adalimumab is effective in these patients (69).
The Productivity Safety and Efficacy: Long-Term
Results in AdaliMumab-Treated Patients With
Crohn's Disease (PYRAMID study) - the largest
and longest study of adalimumab in the management
of moderate to severe Crohn's disease patients - is
an ongoing observational 6-year safety study, started
in September 2007 in 24 countries to investigate
adalimumab safety in the long-term treatment
of Crohn's disease (70). The 3-year data in 5080
patients (9249 cumulative patient-years exposure;
median duration ofexposure 1.66 years) have shown
that adalimumab is well tolerated with low, stable
AE rates between years 2 and 3, without observation
of new clinical concerns or safety signals. Indeed,
the rates of serious infections were lower in
patients receiving adalimumab monotherapy
as compared with those receiving concomitant
immunosuppressants or concomitant corticosteroids
and immunosuppressants (70).
Real-life data for effectiveness of adalimumab
in UC have been obtained in a retrospective
observational Italian study in 88 patients (71).
Adalimumab was effective despite patients had
highly active UC at the start of treatment and
despite most of the patients had been previously
treated with infliximab (71). These data support
those obtained in an uncontrolled prospective study
in which 20 patients with active UC, who had lost
their therapeutic response or developed intolerance
to infliximab, responded well to adalimumab (72).
A retrospective observational study assessed
the need for adalimumab dose escalation and de-
escalation in a large cohort of 720 patients with
active Crohn's disease. The results showed that dose
escalation was required in 34% of patients and that
it was successful in 67%; subsequent de-escalation
following the induction of therapeutic response was
attempted in 54%, and it was successful in 63%; by
this strategy, 71% ofpatients maintained a long-term
response on adalimumab (73).
Rheumatoid arthritis
A German observational study, investigating
the outcomes of adalimumab treatment for RA,
showed that adalimumab had a significant impact on
therapeutic success during routine clinical practice
(74). Factors predictive ofpositive outcome included
high baseline DAS28 and male gender, whereas a
high baseline functional capacity was associated
with reduced gains in functional capacity and older
age; in addition multiple previous biologics were
associated with a reduced likelihood of therapeutic
response (74).
In the Research in Active Rheumatoid Arthritis
(ReAct) study, adalimumab was shown to be effective
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in RA patients previously treated with etanercept or
infliximab in clinical practice. The risk of serious
infections was similar regardless of whether patients
had received anti-TNF therapy or not (75). The study
showed also that adalimumab was effective and
well tolerated either alone or in combination with
traditional DMARDs (76).
Psoriasis
In the long-term open-label extension of the
PRIDE study on efficacy and safety of adalimumab
for moderate to severe chronic plaque psoriasis, the
rate of disease recurrence following adalimumab
discontinuation and subsequent retreatment was
investigated (77). Of 525 patients withdrawn from
adalimumab therapy, 285 had stable psoriasis control.
Of these, 178 (62%) relapsed before the planned
treatment reinitiation at 40 weeks off-therapy.
However, over two-thirds of these patients regained
clinical efficacy following treatment reinitiation (77).
A small observational, prospective study,
comparing monthly versus bi-weekly adalimumab
therapy in 17 patients with moderate-to-severe
chronic plaque psoriasis who responded well to
an initial 24-week course of standard adalimumab
therapy, showed that both regimens achieved control
(defined as PASI75) in most patients by week 24 and
this effect was maintained up to week 60 (78).
Registries
Several national registries provide clinical
data from the real-world setting. The main aim of
rheumatology drug registers is drug safety; however,
they also highlight other important issues that
otherwise would be missed in RCTs, such as drug
usage, real-life long-term effectiveness, the impact
on QoL, the safety of adalimumab treatment in the
clinical setting and related economic issues (79, 80).
A number of registries have examined the safety
of anti-TNF agents. For example, the Research Axed
on Tolerance of Biotherapies (RATIO) registry,
which investigated the incidence of lymphoma and
opportunistic infections in all indications, showed an
increased risk of Legionella pneumophila infection,
a higher risk of tuberculosis with infliximab and
adalimumab, and higher rates of opportunistic
infections and lymphoma with anti-TNF monoclonal
antibodies versus etanercept (81).
In RA, the Dutch RheumatoidArthritis Monitoring
(DREAM) registry compared the remission criteria
used in clinical trials and showed that DAS28 <2.6
and minimal disease activity criteria were achievable
in clinical practice after 6 months of anti-TNF
therapy, although a residual disease activity was
likely to remain. ACRIEULAR remission criteria
were less likely to leave residual disease activity, but
they were less achievable in clinical practice (82).
The analysis of DREAM data showed also that the
risk of serious infections in patients with RA treated
with adalimumab or infliximab was similar, while
being higher than with etanercept (83). Significant
predictors for developing a serious infection
during anti-TNF therapy in RA patients were age,
corticosteroid use, VAS pain, HAQ, TJC28 and the
presence of comorbidities at baseline (84).
DANBIO is a Danish registry of biological
treatments of RA in clinical practice. DANBIO data
from 8 years of treatment were used for a direct
comparison of treatment responses, remission rates,
and drug adherence in patients with RA treated
with adalimumab, etanercept, or infliximab (85).
The analysis of data showed that infliximab had
the lowest rates of treatment response, disease
remission, and drug adherence, while adalimumab
had the highest rates of treatment response and
disease remission, and etanercept had the longest
drug survival rates. The following factors were
identified as negative predictors ofa clinical response
and remission: older age, low functional status, and
concomitant prednisolone (85). Additional data from
DANBIO showed significantly reduced radiographic
progression with anti-TNF treatment as compared
with previous DMARD treatment in 517 patients
with RA (86).
Data from the GISEA registry were used to
analyse the risk of serious infections with long-term
anti-TNF therapy - adalimumab, etanercept and
infliximab - in RA. Findings showed that anti-TNF
therapy is associated with a small, but significant,
risk of serious infections; predictors of risk were
concomitant use of steroids, advanced age, and the
anti-TNF agent - highest for infliximab (65.1/1000
patient-years), followed by adalimumab (23.7/ I000
patient-years), and then etanercept (12.8/1000
patient-years) (87). GISEA data showed also that
the 4-year global drug survival with adalimumab,
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Table 1. Pivotal clinical studies ofadalimumab in immune-mediated disease
Reference (study Patients (N) Design Treatment Endpoints Efficacy outcomes Safety outcomes
acronym)
Keystone et al. (53) Active RA on R. DB. rc, I Adalimumab 40 Week 52 mTSS Change in mTSS greater with AEs similar in
MTX (619) year mgeow Adalimumab vs PBO; week24 adalimumab and PBO;
Week 24 and 52 ACR20 63% and 61% for serious infections
Adalimumab 20 :>20% improvement in Adalimumab 40 and 20 vs 30% higher with
mgqw ACR20 with PBO; week 52 ACR20 Adalimumab (3.8%)
59% and 55% for Adalimumab vs PBO (0.5%);
PBO Week 52 HAQ- 40 and 20 vs 24% with PBO; p<:0.02
disability index HAQ mean change -0.59 and -
0.61, vs -0.25
All p<:O.OOI
Breedveld et al. (54) Early aggressive R, DB, 2 year Adalimumab 40 1- and 2-year ACR50: Combination therapy superior AE profiles were
RA, MTX naive mgeow + MTX mean change in mTSS to mono in all efficacy similar in all 3 study
(PREMIER) (799) outcomes measured: ACR50 groups
MTXalone 62%, vs 46% with MTX and
41% with Adalimumab alone
Adalimumab 40 (p<O.OOI for both); less
radiographic progression at I
mg eow alone and 2 yrs (p<:0.002)
Lovell et al. (55) Juvenile R, Pc. 2 years Adalimumab 24 Disease flares Week-16 ACRpedi30 74% in Safety profiles similar
rheumatoid mg/m' BSA Adalimumab alone and 94% in among groups
(DE038) arthritis (poly- DB weeks 16- (max 40 mg) Week 16 and 32 Adalimumab +MTX
articular) ( 171) 32 based on eow± MTX ACRpedi30
week 16 Disease flares:
response PBO± MTX No MTX: 43% with
Adalimumab and 71% PBO
(p=iJ.03).
With MTX: 37% Adalimumab
and 65% PBO (p~0.02).
Week-48 ACRpedi30:
With MTX - significantly
greater for ADA vs PBO
No MTX - No significant
differences between
Adalimumab and PBO
Van der Heijde et al. Ankylosing R, DB, PC for Adalimumab 40 % ofpts with Week 12, ASAS20: 58.2% AE rate with
(56) spondylitis 24 weeks mgeow ASAS20 at week 12 Adalimumab and 20.6% PBO Adalimumab 75.0%
(315) (p<O.OO I). Week 12 :>50% vs 59.8% with PBO;
(ATLAS) PBO ASAS20 and week 24, improvement in BASDAI p<0.05).
ASAS40. ASAS 45.2% with ADA and 15.9%
partial remission, with PBO (p<O.OOI). ASAS40 Most AEs were mild
individual ASAS and ASAS5/6 response or moderate in
response components: significantly greater with severity.
BASFI, BASDAI Adalimumab vs PBO at weeks
12 and 24 (p<O.OOI).
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Partial remission greater with
Adalimumab vs PBO (22.1%
versus 5.6%; p<O.OOI).
van der Heijde et al. Ankylosing OL for 2 years Adalimumab 40 ~20% improvement in ASAS responses sustained Long-term safety
(57) spondylitis mgeow ASAS20 during long-term treatment; similar to short-term
(311 ) ASAS20 64.5%, ASAS40 profile - Adalimumab
(ATLAS OL PBO ASAS40, ASAS 50.6% and ASAS partial well tolerated. No
extension) partial remission, remission 33.5%~ cases ofTB, CHF,
individual ASAS Changes in ASAS response lupus-like symptoms,
response components; components sustained or or demyelinating
BASFl, BASDAI improved; disease reported.
BASDAI and BASFl improved
over 2 years.
Mease et al. 2005 Psoriatic R, DB, PC 24 Adalimumab 40 ~20% improvement in Week 12: ACR20 58% with Adalimumab was
(58) arthritis (313) weeks mgeow ASAS20 Adalimumab and 14% with generally safe and
PBO (p<O.OOI). well-tolerated
(ADEPT) PBO Change in mTSS;
measures ofjoint and Week 24: ACR20 response
skin disease, disability rates similar to wk 12 and
and QoL change in the mTSS -0.2 with
Adalimumab and 1.0 with
PBO (p<O.OOI).
Week-24 PASI75 in 59% ADA
and 1% with PBO (p<O.OOI).
Disability and QoL measures
significantly improved with
Adalimumab vs PBO.
Mease et al. 2009 Psoriatic OL 2 years Adalimumab 40 ACR20/50170; Compared with 24-week The nature and
(59) arthritis (245) mgeow measures ofjoint responses, inhibition of frequency of AEs
disease and skin radiographic progression and during long-term
(ADEPTOL PBO disease, disability and improvements in joint disease Adalimumab were
extension) QoL, mTSS were maintained during long- consistent with short-
term, open-label Adalimumab. term treatment.
Improvements in skin disease
were maintained, with>20% of
pts achieving PASIIOO.
Menter et al. (60) Psoriasis (1212) R, PC, DB for Adalimumab 40 PASI75 at week 16 Week 16, PAS175 71% with ~
15 weeks then mgeow Adalimumab and 7% with
(REVEAL) re-randomised Week 33-52 PBO.
at week 16 PBO proportion of pts with
based on lost response «50% Weeks 33 to 52, lost response
PASI75 improvement in PASI rate 28% with pts re-
response, response and ~6-point randomised to PBO vs 5% with
treated for I increase in PAS( score continued Adalimumab.
year from week 33)
Saurat et al. (62) Psoriasis (271) R, DB, PC 16 Adalimumab 80 Week 16, proportion 16 weeks PAS175 with AEs similar across
weeks mg then 40 mg of pts achieving ~75% Adalimumab 79.6% and MTX treatment groups.
(CHAMPION) eow improvement in 35.5% (p<O.OOI vs.
PASI75. Adalimumab) and PBO 18.9%
MTX (p<O.OOI vs. Adalimumab).
PBO Complete clearance of disease
. rate 16.7% with Adalimumab,
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7.3% with MTX and 1.9% with
PBO
Adalimumab 57%
improvement in mean PASI
observed at week 4.
Gordon et al. (61) Psoriasis OL extension Adalimumab In pts on continuous 1)& 3) Efficacy was well AE rates were
ofpts from baseline to Adalimumab: maintained over 3 years. consistent with those
(REVEAL OL receiving 3 yrs during REVEAL.
extension) Adalimumab Efficacy aceording to 2)Some pts achieved long-term
in the DB Adalimumab DB response: PASI 75 responses.
phase, groups from week 16 to I) ~75% improvement
by response, 3 3 years in PAS175 at weeks 4)Ellicacy consistent with
year 16 and 33; other 3 groups.
(2) <PASI 75 at week
16;
(3) ~PASI 75 at week
16 with 5G-<75%
improvement in PASI
seore at week 33.
4) Pts who began
adalimumab after 16
weeks PBO
Colombel et al.(63) Crohns disease OL induction Adalimumab 40 Stratification by week % of respondersin remission Adalimumab was
(777) 0-4 weeks rng eow 4 response: decrease significantly greater with well-tolerated
(CHARM) then DB, R to in COAl of,,70 points Adalimumab 40-mg cow and
week 56 Adalimumab 40 40-mg weekly groups versus
% ofweek-4 PBO at week 26 (40%, 47%,
mgqw responders with COAl and 17%, respectively;
<150 (clinical p<O.(Ull)and week 56 (36%,
PBO remission) at week 26 41%, and 12%, respectively;
and 56. p<O.OOI ).
No signilicant differences in
efficacy between adalimumab
eow and weekly dose
regimens.
Schreiber et al. (64) Crohns disease Subgroup Adalimumab Clinical remission and Week 56 clinical remission SAEs with
(777) analysis by response rates at rates significantly greater for Adalimumab lowest
(CHARM subgroups disease PRO weeks 26 and 56 Adalimumab vs PRO in all 3 with disease duration
enrolled into duration: duration subgroups (19% <2 years.
ADHERE follow-on versus 43% for <2 years;
trial) 3 categories: p~0.024; 13% versus 30% for
<2 (F93), 2- 2 to <5 years; p~0.028; 8%
<5 (n~148), versus 28% for ~5 years,
and ~5 years p<O.OOI ).
(n~536)
Shorter duration significant
predictor for higher remission
rate in Adalimumab -treated
pts.
Sandborn et al. (65) Crohu's disease OL for 2 Adalimumab 40 Week 56 maintenanee Remission rates at week 56: Adalimumab
(276) weeks then pts mg wk I and 2; of remission (COAl generally well-
(CLASSIC II) achieving pts in remission <150) Randornised: 79% with tolerated in all pts.
remission at weeks 0 and 4 Adalimumab 40 mg eow and
entered R re-randomised to 83% 40 mg weekly and 44%
phase and Adalimumab 40
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those not mg eow.un mg PBO (p<0.05).
achieving weekly, or PBO
remission OL ADA; 46%
continued on Pts not in
OL ADA for remission:
56 weeks Adalimumab 40
mg eow; dose
increased to 40
mg weekly on
non-response or
flare
Rutgeerts et al. (66) Moderate to R, DB, PC 52 Induction Mucosal healing at Mucosal healing; 5 serious and 3
severe weeks Adalimumab week 12 opportunistic
(EXTEND) ileocolonic 160 mg at week Week 12; 27% Adalimumab infections
Crohn's disease oand 80 mg at vs 13% PBO (p~0.056).
( 135) week 2 then Week 52; 24% and 0,
randomised to; respectively (p<O.OOI).
Adalimumab 40 Week-I 2 remission rates
mgeow (CDE\); 52% for Adalimumab
and 28% for PBO (p=0,006).
PBO Week 52; 28% and 3%
(p<O.OOI ).
Remission (COAl) greater
among pts given continuous
Adalimumab vs PBO at weeks
12 (47% vs 28%; p=0.(21) and
52 (33% vs 9%; p=O.OOI).
Sandborn et al (67) Ulcerative R, DB, PC 52 Adalimumab Remission at weeks 8 Overall remission rates; SAE rate 12% in both
colitis (494) weeks 160 mg week 0, and 52 Week 8; 16.5% Adalimumab groups
(ULTRA 2) 80 mg at week 2, and 9.3% PBO (p~0.l)19)
then 40 mg eow Week 52; 17.3% and 8.5% Serious infections in
(p~0.()()4). 1.6% Adalimumab
PBO and 1.9% PBO.
Anti-TNF naive pts remission
rates;
Week-S: 21.3% Adalimumab
and 11% PBO (p=0.017)
Week 52; 22% and 12.4%
(p=0.029).
Previously received anti-TNFs
remission rates:
Week 8; 9.2% Adalimumab
and 6.9% on PBO (p~0.559)
Week 52; 10.2% and 3%
(p~0.039).
Sandborn et al (68) Ulcerative R, DB, PC 52 Adalimumab Pts assessed for week Clinical remission rate 30.9% No safety concerns
colitis; pts weeks 160 mg week 0, 52 clinical remission, were identified.
(ULTRA 2 subgroup receiving 80 mg at week 2, clinical response, Clinical response rate49.6%
analysis) Adalimumab then 40 mg eow mucosal healing,
achieving steroid-tree remission Mucosal healing rate 43.1 %
clinical response PBO and steroid
at week 8 in discontinuation rates, Responders using
ULTRA 2 (123) overall and by prior corticosteroids (N ~ 90), 21.1%
anti- TNF use. achieved steroid-free remission
and 37.8% were steroid-free at
week 52.
Adalimumab had positive
benefit/risk balance for week 8
and 52 response or remission
without serious AEs or serious
infections.
ACR, American College ofRheumatology; ACRPedi30, American College ofRheumatology Pediatric 30 response; AE, adverse
event; ASAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI,
Bath Ankylosing Spondylitis Functional Index; BSA, body surface area; CDAI, Crohn sDisease Activity Index; DB, double-blind;
eow, every other week; HAQ, Health Assessment Questionnaire; mTSS, modified total Sharp score; MTX, methotrexate; PC,
placebo-controlled; Pts, patients; qw, every week; R, randomised; RA, rheumatoid arthritis; SAE, serious adverse event. PSO,
Placebo; OL, open-label; TB, tuberculosis; CHF, congestive heartfailure; CDEI, Crohn s Disease Endoscopic Index o(Severity
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etanercept and infliximab was <50%, with etanercept
having the best retention rate. Concomitant use of
MTX was a strong predictor of adherence to anti-
TNF therapy (88).
Results from the US Consortium ofRheumatology
Researchers ofNorth America (CORRONA) registry
have supported an early use of anti-TNF therapy,
with disease duration being an independent predictor
of remission in RA patients initiating therapy (89).
A comparison of the effectiveness of adalimumab,
etanercept and infliximab in biologically naive
and switched RA patients showed no differences
in the response or remission rates among the anti-
TNF drugs, although infliximab was associated
with greater persistence in naive patients. In those
who were switched to an anti-TNF, the response,
remission and persistence were lower as compared
with naive patients (90). In an analysis of data from
the RADIUS registry, persistence with etanercept,
infliximab and adalimumab were all similar with
approximate rates of 50% for the first and second-
line use (91).
The British Society for Rheumatology Biologics
(BSRB) Register ~ launched in 2001 to monitor
the real-world effectiveness and safety of anti-TNF
agents and other biologics in RA, and then expanded
to other indications - has produced a wide range of
data on anti-TNF treatment (in comparison with a
non-biologic DMARD control arm) in a range of
indications including RA (92,93), PsA (94), AS (95)
andjuvenile idiopathic arthritis (JIA) (96). In addition
to providing long-term real-world effectiveness and
safety data, the BSRB registry has also enabled the
evaluation of anti-TNF switching patterns (92).
The TREAT registry was initiated to collect long-
term safety data for infliximab and other therapies
used in Crohn's disease. Data from more than 5
years' follow-up show an increased risk of serious
infections in patients with moderate-severe disease,
or treated with either steroids or infliximab or opioid
analgesic. As far as risk of mortality is concerned,
the higher and significant risk was associated either
to age or steroids use or opioid analgesic use (97).
PSOCARE is an Italian registry programme -
initiated by AIFA (the Italian Medicines Agency)
in 2004 and conducted in collaboration with both
scientific dermatological societies (SlDeMaST and
ADOl) and ADIPSO (an association of patients
affected by psoriasis) - designed to evaluate the real-
world long-term outcomes of systemic treatment
of psoriasis, including QoL, predictors of clinical
response and other factors influencing treatment
and outcomes (98-102). Published PSOCARE
data suggest that biologic agents are becoming the
treatment of choice due to their long-term efficacy
and benign tolerability (100). Another PSOCARE
data analysis has shown that higher body mass
index of patients is associated with a reduction in
early clinical response to systemic treatment (102)
and, recently, Gisondi et at. reported that many
systemic treatments used for long-term management
of psoriasis affect a range of metabolic parameters,
such as lipid and glucose levels, liver enzymes and
renal markers; this has been noted particularly with
the retinoid acitretin and cyclosporine, but also with
methotrexate and biological agents (98).
Registries can also be used for comparison
purposes. For example, a control cohort of RA
patients receiving DMARD treatment from a
Norwegian registry was compared with data on
adalimumab therapy from the DE033 open-label
extension study, and it was observed that patients
with RA who received adalimumab experienced
considerably longer periods of work and continuous
employment than patients receiving DMARDs in the
setting of clinical practice (l 03).
Another registry in patients with JIA - the
Juvenile Idiopathic Arthritis Registry (STRIVE) is
currently ongoing (http://c1inicaltrials.gov/ct2/show/
NCT00783510).
Future anti- TNF treatment strategies
Anti-TNF agents have been used predominantly
as second-line therapy in patients failing multiple
DMARD therapy, but clinical data indicate greater
clinical benefits when biologics are used earlier in
the disease course as first-line therapy - resulting in a
prevention of irreversible target organ damage in some
patients, for example, in RA (54, 104) and IBD (8).
The OPTIMA study, conducted in 1032 patients
with active early RA, demonstrated a clear benefit of
initiating anti-TNF therapy early; the combination of
adalimumab with MTX allowed to achieve higher
ACR20/50/70 responses, more clinical remissions,
greater mean reductions in disease activity, no
radiographic progression, and normal functional
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status at 6 months as compared with MTX alone
(p<O.OOI for all) (104). The PREMIER study was
a 2-year, randomized, double-blind clinical trial of
combination therapy with adalimumab plus MTX
versus MTX or adalimumab alone in 799 patients
with early, aggressive RA (54). The results showed
that, in patients who had not been previously treated
with MTX, the initiation with a combination of
adalimumab plus MTX was significantly superior
to either MTX alone or adalimumab alone in
improving signs and symptoms of disease, inhibiting
radiographic progression, and promoting clinical
remission; in addition, tolerability was similar in all
treatment groups (54).
Recommendations for early treatment of RA
from the EULAR guidelines are conservative and
advocate MTX as first-line therapy in patients at risk
of persistent or erosive disease based on its efficacy,
safety profile, and on its beneficial outcomes in
treatment combinations (II, 105). According to
EULAR guidelines, biological therapy should be
considered when poor prognostic factors are present
or in patients with insufficient response to MTX and/or
other traditional DMARDs, and the standard practice
would be to start a TNF inhibitor in combination
with MTX (II). With regard for biological therapy,
guidelines emphasize the importance of a regular
monitoring of disease activity and AEs in guiding
the decisions on treatment choice and changes, and
recommend a careful evaluation of the individual
benefit/risk ratio for each patient (105). Although
RA treatment guidelines advocate a tighter control
of disease activity to prevent progression, many
clinicians would prefer to use anti-TNF agents
earlier in the disease course than treatment guidelines
currently recommend (106, 107).
Recommendations for the use of biologics in
early Crohn's disease state that, while data suggest
that biologic therapies may be more effective in
some patients, current evidence does not support
a widespread early use of biologics in all patients.
Early use of biologics should be considered on an
individual basis in patients with Crohn's disease with
a predictable severe disease course, such as those
with extensive disease, severe rectal disease, young
age, severe perianal diseases at diagnosis and need
for steroids at diagnosis (12, 108).
When considering dermatological indications,
currently there are no data or recommendations
supporting the use of anti-TNF therapy in the early
disease.
Although there are observational data identifying
patients who may be more responsive to anti-TNF
therapies (95) or more likely to succumb to infections
(84), further clinical studies are required to identify
patients most likely to benefit from anti-TNF therapy
early in their disease course. Pharmacogenetic
studies might be able to aid in such identification
(109, 110).
CONCLUSIONS
Targeting TNF by means of biologic anti-TNF
agents is one of several possible ways to bring the
dysregulated immune system under control. This
strategy offers effective therapeutic options with
good tolerability in patients with IMIDs. Since
TNF plays a central role in the pathogenesis and
pathophysiology of all IMIDs, it is not surprising
that five anti-TNF agents - adalimumab, etanercept,
infliximab, certolizumab pegol and golimumab
- have been shown to be effective in one or more
IMIDs. Given the similarity in IMID pathology,
one could expect that the anti-TNF agents would
display similar patterns of effectiveness and have
comparable tolerability profiles. However, this may
not be the case. Structural and pharmacological
differences among the anti-TNF agents are likely
to result in differences in their efficacy and
tolerability in the different IMIDs. Although there
is no definitive evidence supporting differences in
the clinical efficacy of the various anti-TNF drugs,
clear differences in potency, therapeutic dose ranges,
dosing, administration regimens, and propensity for
immunogenicity do exist.
Among the five TNF inhibitors approved for
treatment of 1MIDs, adalimumab has the widest
range of indications and is, therefore, best placed for
treatment of co-occurring inflammatory disorders.
Data from controlled clinical trials, showing an
excellent efficacy and tolerability of adalimumab
in a wide range of indications, supported by real-
world long-term findings from observational studies,
confirm the value of adalimumab as a suited choice
in the management ofIMIDs. Further clinical studies
are required to identify patients who may be more
responsive to anti-TNF therapies and those who are
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most likely to benefit from anti-TNF therapy early in
the disease course, in order to ensure that treatment
can be optimised and tailored to the individual
patient.
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